Inspire Announces Poster Presentations at 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Posted on: Friday, 14 March 2008, 09:00 CDT
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists and collaborators will present information in two poster presentations at the 2008 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting being held March 14 - 18, 2008 in Philadelphia.
The poster entitled "Pharmacokinetic Model of Epinastine, an H1 Antagonist, after Nasal Administration" (C. Crean, P. Ratner, M. Widmann, A. Schaberg, D. Kellerman) contains data from Inspire's Phase 2 trial with epinastine nasal spray for the treatment of Seasonal Allergic Rhinitis (SAR). The poster focuses on modeling the systemic absorption of epinastine when administered nasally and a comparison to oral delivery.
The second poster entitled "The Use of Oral Antihistamines (OA) in Moderate to Severe Dry Eye Patients" (D. Kellerman, T. Durham, A. Schaberg, K. Kuhn, A. Woodring, K. Brazzell, G. Foulks, E. Meltzer) contains data from Inspire's Phase 3 program with Prolacria™ (diquafosol tetrasodium) for the treatment of dry eye. The poster is related to the incidence of use of oral antihistamines by patients with moderate to severe dry eye from the clinical trials.
The posters will be available following the conference on Inspire's website, www.inspirepharm.com.
About Inspire
Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite® (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.
Source: Business Wire
Related Articles
- Panacos to Present Clinical Data on Bevirimat at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
- arGentis Licenses Third Treatment for Dry Eye Syndrome
- Inspire Initiates Phase 3 Trial of Epinastine Nasal Spray for Allergic Rhinitis
- Lantibio and TRB Chemedica Announce Licensing Agreement With Alcon for US Development and Marketing of Dry Eye Drug
- Can-Fite Commences Phase II Clinical Trial for Additional Indication of Dry Eye Syndrome
- Alcon Gets Japanese Patanol OK
- Alcon's Eye Allergy Drug, PATANOL(R) Ophthalmic Solution, Approved in Japan
- Some Treatment for Dry Eye and Mouth
- FDA Asks for More Data on Durham, N.C.-Based Drug Maker's Dry-Eye Treatment
 |
 |
User Comments (0)
RSS Feeds